Aspirin Safety in End-Stage Renal Disease
Aspirin can be used in ESRD patients for secondary prevention after myocardial infarction, but should be avoided for primary prevention due to increased bleeding risk that outweighs uncertain cardiovascular benefits.
Secondary Prevention: Use After MI
- Aspirin is warranted following myocardial infarction in ESRD patients, with observational data showing 43% lower odds of 30-day mortality in dialysis patients who received aspirin post-MI 1
- Additional evidence demonstrates that aspirin use after MI is associated with lower mortality in CKD patients, with similar benefit magnitude as seen in non-ESRD populations (RR 0.64 for 30-day mortality) 2
- For secondary prevention in stroke patients on dialysis, aspirin reduces readmission for recurrent ischemic stroke (HR 0.715) without significantly increasing bleeding risk (HR 0.885) 3
- The 2013 KDIGO guidelines recommend aspirin for secondary prevention in CKD patients without excessive bleeding risk 4
Primary Prevention: Avoid Due to Bleeding Risk
- For primary prevention, aspirin should not be routinely used in ESRD patients because bleeding risk equals or outweighs uncertain cardiovascular benefits 4
- The most recent large cohort study (2025) found aspirin was not associated with reduced cardiovascular events in CKD stages G3-G4 (HR 0.93), but significantly increased major bleeding risk by 45% (HR 1.45) 5
- Meta-analysis of RCTs shows aspirin increases major bleeding risk (RR 1.35) while cardiovascular benefit remains uncertain when observational data is incorporated 6
- Observational data from DOPPS showed hemodialysis patients on aspirin had higher risk of cardiovascular events or MI, though this may reflect confounding by indication 4
Special Considerations for Potential Benefit
- One exception: Patients with elevated lipoprotein(a) ≥50 mg/dL may derive benefit, with 38% lower MI risk (HR 0.62) and 28% lower ESRD progression risk (HR 0.72) without significant bleeding increase 7
- Patients with moderate CKD (eGFR <60 ml/min/1.73 m²) in the TIPS-3 trial showed cardiovascular benefit (HR 0.57) with aspirin, though this was not specifically ESRD patients 8
Bleeding Risk Profile
- Major bleeding risk is consistently elevated across studies, particularly gastrointestinal bleeding 1, 4
- FDA labeling warns that stomach bleeding risk is higher in patients age ≥60, with history of ulcers/bleeding, on anticoagulants, or with ≥3 alcoholic drinks daily 9
- Minor bleeding events increase 3-fold even when major bleeding is not significantly elevated 4
Clinical Algorithm
For ESRD patients presenting with acute coronary syndrome or post-MI:
- Initiate aspirin 75-100 mg daily unless contraindicated 1, 2
- Monitor for gastrointestinal bleeding symptoms 1
For ESRD patients without prior cardiovascular events:
- Do not routinely prescribe aspirin for primary prevention 4, 5
- Consider aspirin only if lipoprotein(a) ≥50 mg/dL is documented, after discussing bleeding risks 7
- Avoid in patients with prior bleeding history, age ≥60, or concurrent anticoagulation 9
For stroke prevention in dialysis patients:
- Aspirin may be used for secondary prevention after ischemic stroke 3
- Avoid for primary stroke prevention given lack of proven benefit 4
Common Pitfalls
- Do not extrapolate general population primary prevention data to ESRD patients - the risk-benefit ratio is fundamentally different due to uremic platelet dysfunction and increased baseline bleeding risk 4
- Aspirin resistance occurs in 43.6% of ESRD patients and is associated with worse outcomes (HR 2.72 for major adverse events), though routine testing is not currently recommended 10
- Underutilization in appropriate settings: Only 67% of ESRD patients receive aspirin after MI compared to 82.4% of non-ESRD patients, representing a significant treatment gap 2